Ovarian Reserve Testing Billing: AMH, AFC, and Day 3 Labs

Ovarian reserve testing is one of the most frequently ordered diagnostic service categories in reproductive medicine — and one of the most inconsistently billed. AMH blood tests, Day 3 lab panels, and antral follicle count ultrasounds are routine in fertility workups, but each carries its own coding nuances, payer coverage limitations, and documentation requirements that practices routinely underestimate. The result is a predictable pattern: undercoded claims, inappropriate bundling, and denied lab tests that should have been preauthorized or billed to the diagnostic benefit rather than the fertility benefit. This article walks through the complete billing picture for ovarian reserve testing — from code selection to payer coverage rules to the most common denial patterns and how to prevent them.

What Ovarian Reserve Testing Involves and Why It Matters for Billing

Ovarian reserve refers to the quantity and quality of a woman's remaining oocyte pool. Clinically, it is assessed through a combination of blood markers and ultrasound findings. The three primary components are the Anti-Müllerian Hormone (AMH) blood test, the Day 3 hormonal lab panel, and the antral follicle count (AFC) ultrasound. Each generates separate billable CPT codes and is subject to different payer coverage policies. Understanding which payer pays for which test — and how to code each correctly — is what separates efficient billing from chronic revenue loss in this service category.

AMH is a hormone secreted by granulosa cells in small antral follicles. Its levels are relatively stable across the menstrual cycle, making it the most convenient single marker to time and order. The Day 3 panel draws on cycle day 3 to measure FSH, LH, and estradiol at the follicular phase baseline; elevated day 3 FSH or a suppressed estradiol indicates diminished reserve. The AFC is a transvaginal ultrasound performed on cycle days 2 through 4 to count visible antral follicles across both ovaries; a low total antral follicle count — typically fewer than 6 to 8 follicles — correlates with poor ovarian response to stimulation.

CPT Codes for Ovarian Reserve Testing

ICD-10 Diagnosis Codes for Ovarian Reserve Testing

Payer Coverage Rules: Diagnostic Testing vs. Fertility Benefit

Most commercial payers draw a sharp distinction between two contexts for ovarian reserve testing: diagnostic evaluation (billed to the general medical or laboratory benefit) and cycle-monitoring assessment as part of an active IVF cycle (billed to the fertility benefit, if covered at all). Billing the wrong benefit line generates denials that are difficult to appeal retroactively because the payer can legitimately argue that the correct benefit was not accessed.

Day 3 FSH and Estradiol (83001 and 82670)

Day 3 FSH and estradiol are covered by most commercial plans under the diagnostic or laboratory benefit as hormonal evaluation of menstrual function. These are standard lab codes that process through the general medical benefit regardless of whether the patient has fertility coverage. Prior authorization is not typically required. Denial risk is low when coded with Z31.41 or N97.9 as the diagnosis; denial risk increases when these codes are submitted with Z31.83 (ART encounter code) as primary, which routes them to fertility benefit adjudication.

AMH (83519)

AMH coverage is more variable than Day 3 labs. Most commercial plans cover AMH as part of an infertility diagnostic workup. Medicare does not cover AMH for fertility purposes under traditional Medicare benefits. Medicaid coverage varies significantly by state. Some high-deductible commercial plans exclude AMH testing under a general fertility exclusion even when the test is ordered in a diagnostic rather than a treatment context. Verify per payer and per plan type at eligibility verification — do not assume commercial coverage equals AMH coverage.

Antral Follicle Count Ultrasound (76830)

The AFC ultrasound is the most frequently denied of the three ovarian reserve testing components. Payers often classify AFC as a fertility monitoring service rather than a diagnostic evaluation, routing it into the fertility benefit — which may be excluded, require prior authorization, or carry a cycle-level limit. Billing AFC as 76830 under Z31.41 with a documented diagnostic indication (evaluating for PCOS, DOR, or establishing baseline before a treatment decision) has the best chance of processing under the general medical benefit. Billing AFC as part of an IVF cycle preparation on a claim with Z31.83 as primary will trigger fertility-benefit adjudication.

Prior Authorization for Ovarian Reserve Testing

Most blood lab components of ovarian reserve testing — FSH, LH, estradiol, AMH — do not require prior authorization when coded under the diagnostic benefit at standard commercial payers. However, several scenarios warrant specific attention before ordering:

• AFC ultrasound (76830): Some payers require authorization when 76830 is billed as a fertility-associated service. Under the diagnostic benefit with Z31.41 as the primary diagnosis, most payers do not require auth. If the patient is in an active fertility treatment cycle with authorization, the AFC may fall under that authorization. Confirm the payer's pathway before the first cycle monitoring visit.
• Fertility benefit manager (FBM) integration: If the patient has a fertility benefit through Progyny, WINFertility, or another FBM, ovarian reserve testing that is part of the cycle workup may fall under the FBM benefit and require their specific authorization process. Billing to major medical for these tests once an FBM benefit is active can result in misrouted claims that the FBM later reclaims.
• Repeated AMH testing: Some payers flag repeat AMH testing within a 12-month window and may require supporting documentation for a second test. If AMH is re-ordered due to a change in clinical status, a new treatment decision, or monitoring of an intervention, document the clinical rationale in the chart note. This note is your defense if the claim pends for medical necessity review.
• Medicare patients: Traditional Medicare does not cover AMH for fertility indications. If your practice sees Medicare-age patients presenting for fertility evaluation, AMH testing will be self-pay. Obtain a signed ABN (Advance Beneficiary Notice) before drawing the blood.

Common Denial Reasons and How to Prevent Them

• AFC billed as 76817 (obstetric ultrasound): Using the obstetric ultrasound code for an AFC in a non-pregnant patient is one of the most commonly cited ultrasound coding errors in fertility billing. The correct code is 76830 (transvaginal, non-obstetric). The 76817 error creates a documentation mismatch — the medical record will reflect no pregnancy, which directly contradicts the obstetric designation of the code — and can flag all past claims using that code for a retrospective audit.
• AMH denied due to code mismatch between practice and reference lab: When the reference lab bills AMH under one code and the practice bills under a different code for the same draw on the same date, the payer may process both as a duplicate or deny one as a conflicting claim. The fix is straightforward: confirm your reference lab's AMH billing code and use it consistently.
• Day 3 labs bundled under E&M by the payer: Some payers automatically bundle lab tests ordered on the same date as a physician visit when both are billed under the same NPI. Day 3 labs billed through the laboratory NPI or under a separate lab account process independently from the office visit. Labs billed under the physician NPI on the same day as a 99213 may be subject to E&M bundling. Verify payer bundling behavior at your major payers and route lab claims through the correct NPI.
• Incorrect diagnosis sequencing on AFC claims: Billing an AFC ultrasound with Z31.83 (ART encounter code) as the primary diagnosis triggers fertility-benefit adjudication even when the AFC was performed as a standalone diagnostic study. If the AFC is diagnostic — not part of an active treatment cycle — sequence Z31.41 or N97.x as primary. If it is part of an authorized treatment cycle, verify that the cycle authorization covers monitoring ultrasounds before filing.
• Inhibin B denied pending information: Inhibin B billed under 86849 (unlisted immunology) routinely pends for manual review. Submit a brief cover memo with the claim identifying the test by name, the assay methodology, and the clinical indication. This shortens the adjudication timeline and reduces the rate of outright denial pending additional information.
• N97.9 used as default when specific etiology is documented: Once test results establish a specific ovarian reserve finding — elevated FSH, low AMH, low AFC consistent with DOR — the medical record supports N97.8 (female infertility of other specified origin), not the unspecified N97.9. Defaulting to N97.9 increases medical necessity scrutiny at payers that use clinical criteria to validate coverage. Use the most specific code the documentation supports.

Downstream Billing Implications of Confirmed Diminished Ovarian Reserve

When ovarian reserve test results confirm diminished ovarian reserve, the ICD-10 coding shifts for all downstream encounters. N97.8 becomes the primary infertility diagnosis driving prior authorization requests for IVF, donor egg consultation, and other ART procedures. This is the most specific code available for DOR-related infertility in ICD-10-CM, but it requires physician documentation — a lab value alone does not establish the code. The physician note must explicitly interpret the results and record a clinical conclusion of diminished ovarian reserve for N97.8 to survive an audit.

For patients with AMH below the clinically actionable threshold who elect fertility preservation (egg freezing) rather than immediate IVF, the coding shifts again: Z31.84 (encounter for fertility preservation) with E28.39 (primary ovarian failure) or N97.8 as a secondary code documenting the medical indication. Coverage for fertility preservation motivated by DOR — as opposed to oncologic preservation — varies significantly across payers and frequently requires medical necessity documentation beyond what is needed for a standard IVF authorization. Many commercial plans treat DOR-motivated egg freezing as elective unless the practice submits a detailed letter of medical necessity with supporting lab values and clinical interpretation. Build this documentation template before the authorization request, not after the first denial.

Building a Charge Capture Workflow for Ovarian Reserve Testing

Practices that consistently capture ovarian reserve testing revenue do so through a standardized intake-to-charge workflow, not through ad hoc physician charge slips. The workflow should address four specific failure points that produce most of the revenue loss in this service category:

• Date of service accuracy: Day 3 labs must be billed on the date of the blood draw, not the date results are reported. Build the charge capture trigger into the draw order, not the results notification. A three-day gap between draw and reporting is common; billing on report date creates date-of-service discrepancies that some payers use to deny as untimely or mismatched.
• AFC ultrasound code confirmation: Ensure the ultrasound log maps AFC exams to 76830 rather than a generic exam code or the obstetric 76817. An AFC-specific note in the ultrasound log description (e.g., "antral follicle count, non-obstetric, transvaginal") reinforces the code selection and supports medical necessity if audited.
• AMH code reconciliation: Establish a standing communication with your reference lab to confirm the exact code they use for AMH on each claim they submit. Document this code in your payer rule library and train billing staff to use it when the practice submits a lab claim for AMH drawn on the same date as a physician visit.
• Diagnosis code tiering by encounter type: Build two separate diagnosis code sets into your charge capture workflow — one for diagnostic ovarian reserve workup encounters (Z31.41 or N97.x as primary) and one for pre-cycle monitoring as part of an authorized ART treatment (N97.8 or E28.x as primary, Z31.83 secondary). The distinction determines which benefit processes the claim and which prior authorization is needed.

Ovarian reserve testing is high-volume, relatively low-complexity billing — which means errors are easy to systematize in the wrong direction. A checklist built around correct codes and correct benefit-line routing will capture more revenue with fewer denials than almost any other single billing improvement a practice can make in the diagnostic services category. The codes are not complicated; the work is ensuring they are applied consistently across every encounter type.